Allogene Therapeutics ALLO
NASDAQ ALLO
$1.33 +0.00 (+0.00%)
At close: Oct 21, 2026 · 4:00 PM EDT

Allogene Therapeutics (ALLO) Total Debt (2018)

Updated

Allogene Therapeutics' Total Debt came in at $139.62 million for Q3 2018.

Analysis

Allogene Therapeutics (ALLO) Total Debt (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 54.91 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 49.04 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 70.82 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 53.91 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 9.59 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 32.35 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 57.30 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 26.25 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 63.19 Bn
10 Allogene Therapeutics 435.17 Mn -666.72 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 139.62 Mn
API Access

Allogene Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=ALLO&period=max&api_key=YOUR_API_KEY